Conversely, we also confirmed that FOXC1 depletion could rescue reduced invasiveness mediated by administration of GSK-126 in two separate human Luminal B breast cancer cell lines in vitro (Supplementary Figure 6C). The gene discussed is FOXC1; the disease is breast carcinoma.